Neumora Therapeutics(US:NMRA) Prnewswire·2025-03-22 00:06Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Neumora common stock in connection with its IPO around September 15, 2023 [1]. - The lead plaintiff deadline for the lawsuit is set for April 7, 2025 [1][3]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2]. - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The Phase Two Trials reportedly lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 3: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the April 7, 2025 deadline, or they can choose to remain absent class members [3]. - The lead plaintiff acts on behalf of all class members and selects counsel to represent the class [3]. Group 4: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]. - The firm encourages Neumora investors who have suffered losses to contact them for more information [4].